EUVIMEDEUVIMED entdecken
Vergleichsstudie

2001–2021 Comparative Persistence of Oral Antipsychotics in Patients Initiating Treatment: Superiority of Clozapine in Time-to-Treatment Discontinuation

Alberto Parabiaghi iD, Alessia A Galbussera, Barbara D'Avanzo, Mauro Tettamanti, Ida Fortino, Angelo Barbato

Pharmacopsychiatry · 01.07.2025 · 58 (04) · 159-169

DOI: 10.1055/a-2437-4366 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pharmacopsychiatry, erschienen am 01.07.2025. Verfasst von Alberto Parabiaghi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit for Quality of Care and Rights Promotion in Mental Health, Department of Health Policy, Istituto di Ricerche Farmacologiche "Mario Negri" - IRCC…. Hauptthemen laut MEDLINE: Antipsychotic Agents, Clozapine, Psychotic Disorders, Time-to-Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Continuous antipsychotic (AP) therapy is crucial for managing psychotic disorders, and its early interruption reflects the drugʼs failure. Real-world epidemiological research is essential for confirming experimental data and generating new research hypotheses.

Methods

The persistence of oral APs in a large population sample from 2000 to 2021 was analyzed by comparing AP prescriptions over this period across four Italian provinces, using dispensing data linked via a record-linkage procedure among regional healthcare utilization databases. We calculated personalized daily dosages and assessed time-to-treatment discontinuation over a 3-month period for patients initiating AP treatment. Treatment persistence was evaluated using Kaplan-Meier curves and Cox regression, with adjustments for age and sex.

Results

Second-generation antipsychotics (SGAs) were favored over first-generation antipsychotics (FGAs), with olanzapine as the most prescribed. Within the study time frame, 42,434 individuals were prescribed a new continuous AP regimen. The analysis revealed 24 significant differences within 28 comparisons. As a class, SGAs demonstrated better treatment persistence than FGAs (HR: 0.76; 95%CI: 0.73, 0.79). Clozapine stood out for its superior persistence, surpassing all other SGAs, notably olanzapine (HR: 0.85; 95%CI: 0.79–0.91) and risperidone (HR: 0.80; 95%CI: 0.74–0.87). Olanzapine and aripiprazole showed better results than both risperidone and quetiapine. Quetiapine showed inferior 3-month persistence in all pairwise comparisons.

Conclusion

The study results provide insight into the performance dynamics among SGAs: clozapine, despite being one of the less frequently dispensed APs in our sample, emerged as a significant prescription choice. The significance of pharmacoepidemiological studies in complementing experimental findings is also underscored.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsClozapinePsychotic DisordersTime-to-TreatmentHumansMaleFemaleMiddle AgedAdultAdministration, OralItalyAged

Substanzen

Antipsychotic AgentsClozapine

Autor:innen und Institutionen

  • Unit for Quality of Care and Rights Promotion in Mental Health, Department of Health Policy, Istituto di Ricerche Farmacologiche "Mario Negri" - IRCCS, Milan, Italy.
  • Laboratory of Geriatric Epidemiology, Department of Health Policy, Istituto di Ricerche Farmacologiche "Mario Negri" - IRCCS, Milan, Italy.
  • Laboratory for Assessing Quality of Care and Services, Department of Health Policy, Istituto di Ricerche Farmacologiche "Mario Negri" - IRCCS, Milan, Italy.
  • Directorate General for Health, Lombardy Region, Milan, Italy.

ORCID-Profile: Alberto Parabiaghi

Zitieren

APA

Parabiaghi, A., Galbussera, A. A., D'Avanzo, B., Tettamanti, M., Fortino, I., & Barbato, A. (2025). 2001–2021 Comparative Persistence of Oral Antipsychotics in Patients Initiating Treatment: Superiority of Clozapine in Time-to-Treatment Discontinuation. Pharmacopsychiatry, 58(04), 159-169. https://doi.org/10.1055/a-2437-4366

Vancouver

Parabiaghi A, Galbussera AA, D'Avanzo B, Tettamanti M, Fortino I, Barbato A. 2001–2021 Comparative Persistence of Oral Antipsychotics in Patients Initiating Treatment: Superiority of Clozapine in Time-to-Treatment Discontinuation. Pharmacopsychiatry. 2025;58(04):159-169. doi:10.1055/a-2437-4366

BibTeX
@article{Parabiaghi2025,
  author = {Parabiaghi, Alberto and Galbussera, Alessia A and D'Avanzo, Barbara and Tettamanti, Mauro and Fortino, Ida and Barbato, Angelo},
  title = {2001–2021 Comparative Persistence of Oral Antipsychotics in Patients Initiating Treatment: Superiority of Clozapine in Time-to-Treatment Discontinuation},
  journal = {Pharmacopsychiatry},
  year = {2025},
  volume = {58},
  number = {04},
  pages = {159--169},
  doi = {10.1055/a-2437-4366}
}
Kostenlos starten →